NEO: Company disclosure · Other company developments

Item 7.01 and Item 8.01, which incorrectly referred to the date “June 20, 2026.” The correct date in each instance is July 20, 2026, consistent with the date of the earliest event reported set forth on the cover page of the Original Form 8-K and the date of the press release furnished as Exhibit 99.1 to the Original Form 8-K. This Amendment is being filed solely to correct those date references. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, Item 7.01 and Item 8.01 of the Original Form 8-K are amended and restated in their entirety as set forth below. Because the press release furnished as Exhibit 99.1 to the Original Form 8-K is unchanged and is not re-furnished with this Amendment, the reference to Exhibit 99.1 in Item 7.01 has been conformed to refer to the Original Form 8-K. Item 9.01 is included to reflect the exhibit filed with this Amendment. Except as expressly set forth herein, this Amendment does not amend, modify or update any other disclosure contained in the Original Form 8-K, and this Amendment does not reflect events occurring after the filing date of the Original Form 8-K. Item 7.01 Regulation FD Disclosure. On July 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below. The information in Item 7.01 of this Current Report and in Exhibit 99.1 to the Original Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth b